2011-10-24T11:40:41-05:00 2010-12-31 BURR PILGER MAYER INC 600 CALIFORNIA STREET SUITE 1300 SAN FRANCISCO CA 94108 990 2010-01-01 943384500 INSTITUTE FOR ONEWORLD HEALTH INST 6503922510 280 UTAH AVENUE NO 250 SOUTH SAN FRANCISCO CA 94080 RICHARD CHIN MD 6503922510 2011-10-20 1 MAGA KISRIEV 4154215757 2010 2016-03-07 17:11:31Z X RICHARD CHIN MD 280 UTAH AVENUE NO 250 SOUTH SAN FRANCISCO CA 94080 36428053 0 X WWW.ONEWORLDHEALTH.ORG X 2000 CA THE INSTITUTE FOR ONE WORLD HEALTH DEVELOPS SAFE, EFFECTIVE AND AFFORDABLE NEW MEDICINES FOR PEOPLE WITH INFECTIOUS DISEASES IN THE DEVELOPING WORLD. 7 6 30 0 0 0 14455688 26173980 0 0 93252 52248 284570 173634 14833510 26399862 5273503 5441466 0 0 6515270 4701962 0 0 121748 10614653 7660915 22403426 17804343 -7569916 8595519 14797131 26215343 1614995 4437688 13182136 21777655 X THE INSTITUTE FOR ONE WORLD HEALTH DEVELOPS SAFE, EFFECTIVE AND AFFORDABLE NEW MEDICINES FOR PEOPLE WITH INFECTIOUS DISEASES IN THE DEVELOPING WORLD. 0 0 2725757 ONEWORLD HEALTH HAS DEVELOPED THE ANTIBIOTIC PAROMOMYCIN INTRAMUSCULAR (IM) INJECTION AS A NEW TREATMENT FOR VISCERAL LEISHMANIASIS. ACTIVITIES INCLUDE:1. CONDUCT CLINICAL STUDY IN BANGLADESH. 2. CONDUCT POST-APPROVAL PROGRAM IN INDIA WITH THE GOAL OF DEVELOPING A SCALABLE, TRANSFERABLE, ACCESS MODEL FOR TREATMENT OF OUTPATIENTS IN INCREASINGLY RESOURCE CONSTRAINED SETTINGS. 3. ESTABLISH COLLABORATIONS WITH GOVERNMENT AGENCIES AND OTHER GLOBAL HEALTH ORGANIZATIONS TO DISTRIBUTE THIS DRUG TO ALL PATIENTS WHO NEED TREATMENT, CONDUCT CLINICAL TRIALS IN OTHER PARTS OF THE AFFECTED WORLD (E.G., BANGLADESH, NEPAL, SUDAN, BRAZIL), AND SEEK REGULATORY APPROVAL IN THESE AND OTHER AFFECTED COUNTRIES. 5937703 5146000 IOWH IS FOCUSING ON THE DEVELOPMENT OF AFFORDABLE MEDICINES THAT WILL EFFECTIVELY TREAT AND/OR PREVENT MALARIA IN VULNERABLE POPULATIONS. THE GOAL IS TO CREATE A STABLE, AFFORDABLE SECOND SOURCE OF ARTEMISININ TO SUPPLEMENT EXISTING NATURAL SOURCES. IN TURN, THIS WILL HELP REDUCE THE PRICE OF ACTS, MAKING THEM MORE ACCESSIBLE TO PEOPLE IN MALARIA AFFLICTED COUNTRIES. 4607357 295466 IOWH FOCUSES PRIMARILY ON DEVELOPING DRUGS TO TREAT MASSIVE FLUID AND ELECTROLYTE LOSS, THE LIFE-THREATENING SYMPTOM OF ACUTE WATERY DIARRHEA ESPECIALLY IN CHILDREN. IN THE MEDIUM AND LONGER TERM, THE ORGANIZATION PLANS TO ADDRESS SIGNIFICANT UNMET NEEDS IN ANTI-MICROBIAL THERAPY AND IN PERSISTENT DIARRHEA. IOWH IS LEVERAGING BOTH OUR IN-HOUSE EXPERTISE AND COLLABORATION WITH PHARMACEUTICAL COMPANIES TO INCREASE THE PROBABILITY FOR TECHNICAL SUCCESS TO DEVELOP A NEW TREATMENT FOR ACUTE WATERY DIARRHEA. 662703 IOWH IS CURRENTLY DEVELOPING A NEW TREATMENT FOR HELMINTHIASIS FOR USE IN MASS DRUG ADMINISTRATION PROGRAMS IN SOUTH ASIA. 662703 13933520 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 29 0 1 30 1 0 1 IN 0 0 0 1 1 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X RICHARD CHIN MD 6503922510 280 UTAH AVENUE NO 250 SOUTH SAN FRANCISCO CA 94080 MENGHIS BAIRU MD 5.00 X 0 0 0 FREDERICK W KYLE 15.00 X 0 0 0 NIGEL TEN FLEMING PHD 5.00 X 0 0 0 HERBERT MONTGOMERY 15.00 X 0 0 0 KEITH OLSON 5.00 X 0 0 0 TOM BREWER 5.00 X 0 0 0 RICHARD CHIN 40.00 X X 365525 0 27766 ROBERT FARRELL 40.00 X 143376 0 27629 MATTHEW WICKLER 40.00 X 51023 0 10598 JULIE CHENG 40.00 X 219415 0 11119 TUE NGUYEN 40.00 X 212160 0 45504 DEBRA VALLNER 40.00 X 219771 0 31271 MARIE LENNARTSSON 40.00 X 135516 0 8671 HEATHER KELLY 40.00 X 126233 0 13845 RHONDA SARNOFF 40.00 X 122073 0 36492 EUGENIO DE HOSTOS 40.00 X 117186 0 26674 NERISSA DEL ROSARIO 40.00 X 116545 0 17365 1828823 0 256934 10 0 1 0 MASON S BRUTSCHY 39 LLOYDEN DRIVE ATHERTON CA 94027 FINANCE 220263 FOLEY & LARDER LLP 55 SOUTH FLOWER STREET LOS ANGELES CA 90071 LEGAL 132270 BURR PILGER & MAYER 600 CALIFORNIA ST SUITE 1300 SAN FRANCISCO CA 94028 AUDIT & TAX 129437 ENSANTE CONSULTING 503 OSPREY COURT REDWOOD CITY CA 94065 BUSINESS DEVELOPMENT 112815 4 26173980 26173980 100956 100956 137680 137680 9979483 10028191 -48708 -48708 -48708 MISCELLANEOUS INCOME 35954 35954 35954 26399862 -12754 0 238636 120000 120000 5321466 5321466 1476130 884245 591885 2071816 956896 1052186 62734 929809 478461 431088 20260 224207 109751 108505 5951 160154 128041 32113 209437 209437 23114 23114 93885 36214 57491 180 552164 317439 227486 7239 597436 469260 126858 1318 41534 27004 14530 267502 218368 47182 1952 48875 3917 44958 CONTRACTED SERVICES 3294148 3056655 231192 6301 PROFESSIONAL FEE 1977901 1568395 404617 4889 COMMUNICATIONS 112174 58930 52762 482 LICENSES, FEES & SUBSCR 94554 49301 42178 3075 POSTAGE & PRINTING 54083 33672 13135 7276 133954 95505 38358 91 17804343 13933520 3749075 121748 577397 1420827 1062225 1054750 55642 18341 197258 230886 948471 835180 196258 113291 11380530 22185000 1284935 1152011 42886 40237 14797131 26215343 1614995 4437688 1614995 4437688 X 109445 213878 13072691 21563777 13182136 21777655 14797131 26215343 8595519 0 X 0 1 1 X 0 X UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER SAN FRANCISCO CA KALA-AZAR MEDICAL RESEARCH CENTRE MUZAFFARPUR IN RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 660253 576125 84128 255263 232596 22667 32955 26459 6496 113291 STOCKS, MUNI BONDS, FIXED INCOME SEC. (DETAIL AVAILABLE UPON REQUEST) 22185000 F 22185000 26399862 17804343 8595519 0 8595519 26458636 81888 81888 26376748 23114 23114 26399862 17863117 81888 81888 17781229 23114 23114 17804343 EAST ASIA AND THE PACIFIC 2 8 PROGRAM SERVICES RESEARCH VISCERAL LEISHMANIASIS PROGRAM 255649 EUROPE 0 0 PROGRAM SERVICES RESEARCH MALARIA PROGRAM 5146000 8 0 8 5401649 0 5401649 0 0 0 0 0 0 METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: ACCRUAL METHOD OF ACCOUNTING, IN ACCORDANCE WITH U.S. GAAP. 1 X X X 1 1 0 0 0 0 0 0 0 RICHARD CHIN 308325 0 50000 0 7200 0 0 0 27766 0 393291 0 0 0 ROBERT FARRELL 143376 0 0 0 0 0 0 0 27629 0 171005 0 0 0 JULIE CHENG 215624 0 3791 0 0 0 0 0 11119 0 230534 0 0 0 TUE NGUYEN 208369 0 3791 0 0 0 0 0 45504 0 257664 0 0 0 DEBRA VALLNER 206480 0 13291 0 0 0 0 0 31271 0 251042 0 0 0 RHONDA SARNOFF 118782 0 3291 0 0 0 0 0 36492 0 158565 0 0 0 FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS REVIEWED BY CHIEF EXECUTIVE OFFICER, INTERIM CFO & BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ANNUAL DISCLOSURE OF ANY POTENTIAL CONFLICT IS REQUIRED OF ALL OFFICERS AND KEY ORGANIZATIONAL MEMBERS. FURTHER, THERE IS A DUTY TO DISCLOSE ANY CONFLICT AT THE TIME OF OCCURRENCE. POTENTIAL CONFLICTS OF INTEREST ARE REFERRED TO THE APPROPRIATE BOARD COMMITTEE FOR REVIEW OF ALL MATERIAL FACTS AND CIRCUMSTANCES. ONLY THE INDEPENDENT MEMBERS OF THE COMMITTEE ARE ALLOWED TO VOTE AND DETERMINE WHAT ACTION MUST BE TAKEN FOR THE SAKE OF IOWH. DECISIONS REGARDING A DIRECTOR WITH A MATERIAL FINANCIAL INTEREST IN A TRANSACTION MUST BE RATIFIED BY THE FULL BOARD. FORM 990, PART VI, SECTION B, LINE 15 IT IS DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE AND UPON REQUEST